295 results on '"Gioia, Stefania"'
Search Results
2. Episodic overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis
3. Porto-sinusoidal vascular disorder (PSVD): Application of new diagnostic criteria in a multicenter cohort of patients
4. Application of ultrasonography-elastography score to suspect porto-sinusoidal vascular disease in patients with portal vein thrombosis
5. Porto-sinusoidal vascular liver disorder with portal hypertension: Natural history and long-term outcome
6. Real-world experience with long-term albumin in patients with cirrhosis and ascites
7. Clinical outcomes and prognostic factors in non-cirrhotic non-neoplastic patients with portal vein thrombosis: A single-centre experience
8. New Indications for TIPSs: What Do We Know So Far?
9. Lactulose in Liver Cirrhosis
10. FRI-047-YI Predictors of ascites resolution in patients with cirrhosis receiving long-term albumin treatment. Results from a real-world study in Italy (Real-ANSWER)
11. SAT-131 End-procedural complete hemodynamic response may not be essential for the clinical success of tips in patients with cirrhosis
12. Liver Transplantation for Porto-Sinusoidal Vascular Liver Disorder: Long-term Outcome
13. Risk of falls in patients with cirrhosis evaluated by timed up and go test: Does muscle or brain matter more?
14. Long‐term albumin improves the outcomes of patients with decompensated cirrhosis and diabetes mellitus: Post hoc analysis of the ANSWER trial.
15. Coil- and Plug-Assisted Transvenous Retrograde Obliteration (CARTO/PARTO) in the Treatment of Gastric Varices: A European Single Centre Experience.
16. The egg and the chicken: Does sarcopenia or cognitive impairment come first?
17. The Management of Hepatic Encephalopathy from Ward to Domiciliary Care: Current Evidence and Gray Areas
18. Episodic overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis
19. The additive value of sarcopenia, myosteatosis and hepatic encephalopathy in the predictivity of model for end-stage liver disease
20. Episodic Precipitant–induced Hepatic Encephalopathy Treatment: The Ideal Trial Is Still Lacking
21. PHES scores have limited impact on the risk of overt HE in patients with minimal HE.
22. Minimal hepatic encephalopathy is associated with a higher risk of overt hepatic encephalopathy and poorer survival.
23. Minimal hepatic encephalopathy is associated with a higher risk of overt hepatic encephalopathy and poorer survival
24. Transjugular Intrahepatic Portosystemic Shunt Placement: Effects on Nutritional Status in Cirrhotic Patients
25. Association between gut‐derived endotoxins and porto‐sinusoidal vascular disorder with portal hypertension
26. P9 Minimal Hepatic Encephalopathy Is Associated With an Increased Risk of Overt Hepatic Encephalopathy and Poorer Prognosis – A Multicenter Study
27. Natural history of patients with non cirrhotic portal hypertension: Comparison with patients with compensated cirrhosis
28. Causes and Management of Non-cirrhotic Portal Hypertension
29. Porto-sinusoidal vascular disorder (PSVD): Application of new diagnostic criteria in a multicenter cohort of patients
30. Primary Prophylaxis of Overt Hepatic Encephalopathy: Is It Time to Consider It?
31. Role of gut-derived endotoxins in porto-sinusoidal vascular disease
32. Prevalence of minimal hepatic encephalopathy in patients with cirrhosis: a multicenter study
33. Real-word experience of long-term albumin treatment in a large cohort of patients with cirrhosis and ascites (Real-Answer study)
34. Porto sinusoidal vascular liver disorder: natural history and long-term outcome
35. Albumin levels are associated with portal hypertension in patients with porto sinusoidal vascular disorder
36. Sarcopenia Is Risk Factor for Development of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Placement
37. The Management of Hepatic Encephalopathy from Ward to Domiciliary Care: Current Evidence and Gray Areas.
38. Prevalence of Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis: A Multicenter Study.
39. Management of Hepatic Encephalopathy Not Responsive to First-Line Treatments
40. Albumin for cognitive impairment after TIPS: A road to be explored
41. Hepatic encephalopathy in patients with non-cirrhotic portal hypertension: Description, prevalence and risk factors
42. Hepatic encephalopathy – recent advances in treatment and diagnosis
43. Old and New Precipitants in Hepatic Encephalopathy: A New Look at a Field in Continuous Evolution
44. A Model for Predicting Development of Overt Hepatic Encephalopathy in Patients With Cirrhosis
45. Minimal Hepatic Encephalopathy Affects Daily Life of Cirrhotic Patients: A Viewpoint on Clinical Consequences and Therapeutic Opportunities
46. Hepatic Encephalopathy Is Associated with Persistent Learning Impairments Despite Adequate Medical Treatment: A Multicenter, International Study
47. No effect of albumin infusion on the prevention of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt
48. Prevention of post-tips hepatic encephalopathy: The search of the ideal candidate
49. Determinants of prognosis in cirrhosis: a new outlook
50. Risk factors for hepatic encephalopathy and mortality in cirrhosis: The role of cognitive impairment, muscle alterations and shunts
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.